Cargando…
Time Spent for Activation of Non-Profit Studies in Oncology in Italy
AIM: The aim of this paper is to describe the time spent to activate oncological non-profit clinical trials promoted in Italy by the National Cancer Institute of Naples, following the implementation of recent European laws. METHODOLOGY: Data about the process of activation of 5 non-profit multicentr...
Autores principales: | De Feo, Gianfranco, Signoriello, Simona, Bryce, Jane C., Del Giudice, Antonia, Canzanella, Giuliana, Crudele, Federika, Romano, Fiorella, de Matteis, Giovanni, Florio, Manuela, Falasconi, Fabiano, Savio, Alfonso, Giordano, Pasqualina, Daniele, Gennaro, Iaccarino, Mario, Piccirillo, Maria Carmela, Di Maio, Massimo, Morabito, Alessandro, Gallo, Ciro, Perrone, Francesco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912338/ https://www.ncbi.nlm.nih.gov/pubmed/20686686 http://dx.doi.org/10.1371/journal.pone.0011864 |
Ejemplares similares
-
Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials
por: Di Maio, Massimo, et al.
Publicado: (2012) -
Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011) -
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan
por: Chiodini, Paolo, et al.
Publicado: (2020) -
Efficiency and profitability in US not-for-profit hospitals
por: Rosko, Michael, et al.
Publicado: (2020) -
Reply to: “Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma”
por: Crudele, Lucilla, et al.
Publicado: (2023)